With the 2026 flu season approaching, health experts are recommending individuals receive their annual flu shots between September and October for optimal protection. While traditional vaccines are widely available across the United States, a new mRNA flu vaccine has been approved, offering enhanced efficacy for specific age groups and potentially reshaping future immunization strategies.
According to federal data, influenza accounts for approximately 45,000 deaths annually in the United States, with vaccination efforts preventing an estimated 10 million flu-related illnesses last year. The Centers for Disease Control and Prevention (CDC) advises flu vaccination for everyone aged six months and older. Dr. Stephen Thacker, a pediatric infectious diseases specialist at the Medical University of South Carolina, suggests September vaccinations for areas expecting an earlier surge, but generally recommends October, and no later than November. It typically takes about two weeks for the vaccine to become effective, as noted by Arizona primary care physician Dr. Michael Dunn.
The current flu vaccines have been updated to target three strains, including the H3N2 strain that was dominant last winter. Dr. Shalika Katugaha, an infectious disease specialist at Baptist Health, emphasized that even if there isn’t a perfect match with circulating viruses, the vaccine still offers benefits, reducing the risk of serious illness, hospitalization, and death. High-risk groups, including children under five, pregnant individuals, those with compromised immune systems, and seniors over 65, are particularly encouraged to vaccinate.
Introducing Moderna’s mFLUSIVA: The First mRNA Flu Vaccine
A significant development for the 2026 flu season is the introduction of mFLUSIVA, the first mRNA flu vaccine, developed by Moderna and approved for individuals aged 50 and older. Studies indicate that mFLUSIVA is between 25 and 27 percent more effective in protecting this demographic compared to traditional flu shots. However, reports from the Fernandina Observer note that the mRNA vaccine has been linked to more side effects, such as soreness at the injection site, fatigue, muscle aches, and headaches, when compared to the standard vaccine typically given to older adults.
The mRNA technology utilized in mFLUSIVA represents a notable advancement, as it allows for a more rapid adaptation of vaccine composition to address new viral strains, a process that is much slower with traditional egg-grown vaccines. Despite its innovative potential, the immediate availability of mFLUSIVA at pharmacies is uncertain. This is partly due to operational challenges in ordering and potential insurance coverage questions stemming from the suspension of the CDC’s Advisory Committee on Immunization Practices (ACIP), which sets vaccine policy.
Broader Trends in Vaccine Uptake and Public Health Guidance
Current data suggests a concerning trend in vaccine uptake across the U.S., with less than half of adults having received immunization against any respiratory virus by November 2025, according to a poll from the National Foundation for Infectious Diseases. This includes flu and COVID-19 vaccines. Dr. Katugaha advises against waiting for the mRNA vaccine if traditional flu shots are available, emphasizing that any available vaccine should be taken in September or October to ensure timely protection. Additionally, flu vaccines can be administered concurrently with COVID-19, RSV, or pneumococcal vaccines.
The broader context of vaccine policy has been complicated by the suspension of the ACIP by the Trump administration, following controversies regarding expert panel selection. While the administration, including Health and Human Services Secretary Robert F. Kennedy Jr., has expressed doubts about the safety of some vaccines, it continues to recommend annual flu vaccination. The advent of mRNA technology, proven effective with major COVID-19 vaccines that are credited with preventing over 2.5 million deaths worldwide, highlights how scientific innovation can swiftly address global health threats, underscoring the international significance of these developments amidst ongoing public health debates.
As the flu season progresses, individuals should monitor local and state health messaging for increasing flu cases and vaccine availability. Key aspects to watch include the rollout and accessibility of the new mRNA vaccine, the clarity of public health guidance in the absence of an active ACIP, and overall vaccination rates, which will collectively determine the health outcomes of the upcoming season.
Image: The Independent
Sources consulted
- The Independent: When should you get your flu shot? Here’s what the experts say
- News4JAX: News4JAX+ at 10 a.m.: Things to know about the new Flu Vaccine
- Fernandina Observer: It’s time to schedule flu vaccination
Adrian Velk is a global affairs journalist focused on breaking news, geopolitics, and societal trends. With a sharp eye for detail and a commitment to accuracy, he delivers timely reporting that helps readers understand the fast-moving world around them. His work blends factual depth with clear storytelling, making complex events accessible to a broad audience.
